Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever.
Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes
June 3, 2024 Australian BiotechLatest Video
New Stories
-
The 'Week in Review' Podcast - 18 October
October 18, 2024 - - Podcast -
New research uncovers Australian women are often reluctant to openly talk about menopause
October 18, 2024 - - Latest News -
The danger of this outlier is reflected in the disconnect with another policy process
October 18, 2024 - - Latest News -
Pharmac seeking bids from suppliers of COVID-19 vaccines
October 17, 2024 - - Latest News -
Auditor General launches audit of the procurement of onshore vaccine manufacturing facilities
October 17, 2024 - - Latest News -
This has happened before and the response should be the same. No.
October 17, 2024 - - Latest News -
Vitalis and Servita partner to lead healthcare digital transformation in Queensland
October 17, 2024 - - Latest News